Phase II study of Eribulin in combination with Gemcitabine for the First-line Treatment of Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer. Protocol ERIGE.
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
Price : $35 *
At a glance
- Drugs Eribulin (Primary) ; Gemcitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ERIGE
- 06 Jun 2017 Results (n=83), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 12 Dec 2015 Trial design presented at the 38th Annual San Antonio Breast Cancer Symposium
- 06 Aug 2014 New trial record